Summary
Bipolar disorder (BD) is a chronic and debilitating mental disorder, that affects 2-3% of the population. It impacts quality of life, cognition, and is a leading cause of suicide and all-cause mortalities. Most patients are taken into clinical care during acute episodes, which puts the burden on psychiatrists to make fast, yet accurate diagnostic decisions. However, unlike most medical conditions, psychiatric diagnoses are subjective. This paired with the complexity of its clinical presentation, BD is the most misdiagnosed and underdiagnosed psychiatric condition. More objective scales used in research lack clinical application, due to time constraints and high burden on the patient. AI-DIAGNOSE wants to disrupt the state of the art of BD diagnosis through a completely novel approach: developing an automatized and fast tool for objective detection of BD and psychotic symptoms based on physiological audiovisual biomarkers and machine learning (ML). The timing of the project is supported through recent evidence, from the host, the applicant, and others, showing that speech and eye movement are promising physiological biomarkers. In a pilot study, I found that ML algorithms based on speech patterns could predict the presence of psychiatric diagnosis, and differentiate patients with and without psychosis. Eye‐tracking datasets provide insights regarding information processing patterns, and have shown potential as diagnostic biomarkers. Although eye movement and speech patterns are promising biomarkers as they can be acquired fast and without putting high burden on the patient, they have not been combined yet for psychiatric diagnostic purposes. The project will be the first to develop such a multi-modal ML diagnostic tool for BD and psychosis in BD. We will test its accuracy against the research gold standard in the field within a large patient cohort (140 patients, 70 controls). If successful, this will a major step towards precision medicine within BD and psychiatry
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101109497 |
| Start date: | 01-01-2024 |
| End date: | 31-12-2025 |
| Total budget - Public funding: | - 181 152,00 Euro |
Cordis data
Original description
Bipolar disorder (BD) is a chronic and debilitating mental disorder, that affects 2-3% of the population. It impacts quality of life, cognition, and is a leading cause of suicide and all-cause mortalities. Most patients are taken into clinical care during acute episodes, which puts the burden on psychiatrists to make fast, yet accurate diagnostic decisions. However, unlike most medical conditions, psychiatric diagnoses are subjective. This paired with the complexity of its clinical presentation, BD is the most misdiagnosed and underdiagnosed psychiatric condition. More objective scales used in research lack clinical application, due to time constraints and high burden on the patient. AI-DIAGNOSE wants to disrupt the state of the art of BD diagnosis through a completely novel approach: developing an automatized and fast tool for objective detection of BD and psychotic symptoms based on physiological audiovisual biomarkers and machine learning (ML). The timing of the project is supported through recent evidence, from the host, the applicant, and others, showing that speech and eye movement are promising physiological biomarkers. In a pilot study, I found that ML algorithms based on speech patterns could predict the presence of psychiatric diagnosis, and differentiate patients with and without psychosis. Eye‐tracking datasets provide insights regarding information processing patterns, and have shown potential as diagnostic biomarkers. Although eye movement and speech patterns are promising biomarkers as they can be acquired fast and without putting high burden on the patient, they have not been combined yet for psychiatric diagnostic purposes. The project will be the first to develop such a multi-modal ML diagnostic tool for BD and psychosis in BD. We will test its accuracy against the research gold standard in the field within a large patient cohort (140 patients, 70 controls). If successful, this will a major step towards precision medicine within BD and psychiatryStatus
SIGNEDCall topic
HORIZON-MSCA-2022-PF-01-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
